{"filings":[{"id":1967719,"accession_number":"0001606498-26-000115","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-07-30T20:05:40+00:00","items":["1.01","1.02","2.01","2.03","3.01","3.03","5.01","5.02","5.03","7.01","9.01"],"status":"ready","headline":"AIP completes acquisition of Avanos for $1.272B; stockholders receive $25.00/share cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal valued at ~$1.272B; Avanos stockholders get $25.00 per share in cash.","Avanos common stock delisted from NYSE; company becomes private.","New board: David Pacitti CEO, Scott Galovan CFO, John Fischer General Counsel.","Credit agreement: $675M term loan, $100M DDTL, $100M revolver, matures 2033.","Prior directors resigned; Joel Rotroff (AIP) initially appointed then replaced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1802519,"accession_number":"0001606498-26-000096","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-07-22T20:06:52+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Avanos stockholders approve $25/share acquisition by American Industrial Partners","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["99.75% of votes cast in favor, representing ~74.96% of outstanding shares.","Deal price: $25.00 per share in cash for each Avanos common share.","All required regulatory approvals received; transaction expected to close by July 27, 2026.","Acquisition by AIP will take Avanos private; closing subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1645885,"accession_number":"0001606498-26-000093","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-07-14T23:18:06+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avanos supplements proxy with additional M&A details amid stockholder lawsuits; merger on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two stockholder lawsuits filed June 29-30, 2026 in NY Supreme Court seeking to enjoin merger; demand letters also received alleging proxy deficiencies.","Avanos voluntarily supplements proxy with additional background on AIP's contact with UBS, UBS conflict disclosure, and estimated UBS fee of not more than $5M.","JP Morgan's public trading multiples analysis shows implied per share equity value range of $12.75-$23.50 vs. merger consideration of $25.00.","JP Morgan's selected transactions analysis shows implied per share equity value range of $9.75-$21.75 vs. merger consideration of $25.00.","Special meeting still set for July 22, 2026; board continues to unanimously recommend approval of merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1400756,"accession_number":"0001606498-26-000085","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-07-02T14:10:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos receives all regulatory approvals for AIP acquisition; closing expected by July 27","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All required regulatory approvals received for acquisition by American Industrial Partners affiliates.","Transaction expected to close no later than July 27, 2026, subject to stockholder approval and other conditions.","Special stockholder meeting to approve the merger scheduled for July 22, 2026.","Avanos CEO David Pacitti and AIP Partner Joel Rotroff commented positively on the milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94055,"accession_number":"0001606498-26-000061","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical announces Q1 2026 results; filing includes no financial figures","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release issued May 5, 2026 covering three months ended March 31, 2026.","No specific revenue, EPS, or segment data available in the filing excerpt.","Investors should refer to the full press release for detailed results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":182200000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94054,"accession_number":"0001606498-26-000046","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Avanos Medical to be acquired by AIP for $25/share, $1.272B enterprise value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Avanos stockholders receive $25.00 per share in cash; enterprise value approx. $1.272B.","Premium of 72.1% to April 13 closing price and 82.8% to 30-day VWAP.","Acquisition unanimously approved by Avanos Board; expected to close H2 2026.","Closing conditions include stockholder approval and HSR clearance; no financing condition.","Avanos common stock will be delisted from NYSE; 2026 annual meeting postponed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106139,"accession_number":"0001606498-26-000017","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avnos Medical raises CEO David Pacitti's annual LTIP target to $5.5M from $5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board increased CEO David Pacitti's annual LTIP target from $5M to $5.5M.","The change is effective for 2026 under the 2021 Long Term Incentive Plan.","The $500k increase represents a 10% rise in target value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106138,"accession_number":"0001606498-26-000007","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Avanos adds two directors in cooperation deal with activist Radoff","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["James Cunniff (CEO of Electromed) and William Burke (former EVP/CFO Haemonetics) nominated for board at 2026 annual meeting.","Bradley Radoff withdraws his director nomination and agrees to standstill and voting commitments through early 2027.","Agreement resolves potential proxy contest; Radoff expresses confidence in new directors and Avanos' future.","Board chair says Cunniff and Burke bring complementary operating and financial expertise to support strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106137,"accession_number":"0001606498-26-000002","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.","Q4 GAAP net loss $1.3M ($0.03 loss per share); adjusted net income $13.4M ($0.29 adjusted EPS).","Full-year 2025 net loss $72.9M; adjusted EBITDA $86.8M vs $107.6M in 2024.","Recorded $77M non-cash goodwill impairment on PM&R segment in Q2 2025.","2026 guidance: net sales $700-720M; adjusted diluted EPS $0.90-1.10."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":701200000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106136,"accession_number":"0001628280-26-001991","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos Medical presents at JP Morgan Healthcare Conference; no material financial updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dave Pacitti presented company strategy at JP Morgan Healthcare Conference on January 13, 2026.","No specific financial guidance, earnings numbers, or material new initiatives were provided in the exhibited slide deck.","The presentation primarily consisted of forward-looking statements and general business direction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122428,"accession_number":"0001606498-25-000135","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos eliminates CCO and GC roles; final severance includes full vesting of James's 16,300 RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company eliminated Chief Commercial Officer and General Counsel positions effective Dec 1, 2025 as part of restructuring.","Kerr Holbrook (CCO) and Mojirade James (GC) terminated; responsibilities reallocated.","Severance: Holbrook $1,535,417; James $1,425,665; plus COBRA, prorated bonuses, equity vesting.","16,300 time-based RSUs granted to James on April 22, 2025 vested fully on Dec 1, 2025.","Unvested awards treated as retirement; time-based PRSUs pro-rata vested, performance-based vest at end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122430,"accession_number":"0001606498-25-000129","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical files Q3 2025 earnings release; detailed results not provided in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release for three and nine months ended September 30, 2025 furnished as Exhibit 99.1.","No specific financial figures (revenue, EPS, segments) available in the filing materials submitted.","Earnings release date: November 5, 2025; coverage period Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":520300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122429,"accession_number":"0001606498-25-000126","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos eliminates Chief Commercial Officer and General Counsel positions; two executives to leave Dec 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kerr Holbrook (CCO) and Mojirade James (General Counsel & Secretary) terminated effective Dec 1, 2025 due to position elimination in restructuring.","Severance: Holbrook ~$1.54M, James ~$1.43M, plus 12 months COBRA premium coverage.","Unvested equity: time-based RSUs vest pro rata; performance-based RSUs vest at end of period; stock options exercisable for 5 years.","Prorated 2025 bonuses at target approved for both executives.","Payments conditional on separation agreement, general release, and continued compliance with confidentiality/non-solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139126,"accession_number":"0001606498-25-000123","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos Medical acquires Nexus Medical for TKO anti-reflux connector; accretive to revenue/ EPS","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Nexus Medical, LLC, maker of TKO needleless connector technology for NICU/PICU.","Financed with available cash; expected to be immediately accretive to both revenue growth and EPS.","Adds complementary technology to Avanos' Specialty Nutrition Systems business.","No purchase price disclosed; target is a privately held company based in Lenexa, Kansas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139125,"accession_number":"0001606498-25-000106","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.","Adjusted EPS $0.17 vs $0.34; adjusted EBITDA $17.0M vs $26.8M YoY.","Recorded $77M goodwill impairment in PM&R segment due to market cap pressure.","Divested HA product line (TriVisc, GenVisc 850) to Channel-Markers Medical on July 31, 2025.","Appointed Scott Galovan as CFO effective Aug 1, 2025; CEO Pacitti appointed to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":342500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156650,"accession_number":"0001606498-25-000087","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.","Net income $6.6M ($0.14 diluted EPS) vs $0.5M ($0.01) a year ago; adjusted net income $12.0M ($0.26 adjusted EPS).","SNS segment net sales $101.1M with 8.7% volume growth driven by enteral feeding and neonate solutions.","PM&R segment net sales $56.2M; RFA product sales grew 8.2% from ESENTEC/TRIDENT momentum.","2025 revenue guidance reaffirmed at $665-$685M; adjusted EPS guidance lowered to $0.75-$0.95 due to tariff impacts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":167500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156649,"accession_number":"0001606498-25-000085","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos Medical finalizes separation with Officer Greiner; $2.1M severance, accelerated RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cash severance of $2.1M plus prorated 2025 bonus based on actual performance, paid in 2026.","Immediate vesting of 44,189 TRSUs granted Oct 29, 2024 and 10,000 TRSUs granted Dec 3, 2024.","Consulting engagement as independent contractor through May 16, 2025 with $50,000 fee.","COBRA premium coverage for six months at 100% of monthly premiums.","Separation conditioned on non-revocation of release and compliance with confidentiality agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156646,"accession_number":"0001606498-25-000081","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos appoints Jason Pickett as Interim CFO; Greiner departs with $2.1M severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Greiner departs after not being offered comparable role post-interim CEO; receives $2.1M severance, prorated bonus, $50K consulting fee.","Jason Pickett named Interim CFO and Treasurer effective April 14; salary $350K/year plus $30K/month stipend.","Pickett granted special $200K TRSU award with 12-month vesting on April 22.","Warren Machan transitions from Interim CFO to consultant through April 30 at $60K/month; no second bonus.","Greiner's 54,189 special TRSUs vest immediately; all other unvested equity forfeited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156648,"accession_number":"0001606498-25-000078","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avanos shareholders approve all proposals at 2025 annual meeting, including 2.25M share increase for LTIP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with 85.8% to 90.3% of votes cast; broker non-votes excluded.","Deloitte & Touche ratified as auditor for 2025 with 94.7% of votes cast in favor.","Say-on-pay advisory vote passed with 86.7% of votes cast for, 11.4% against.","Amendment to 2021 Long Term Incentive Plan approved: 2,250,000 new shares added to reserve.","93.6% of outstanding shares represented at the meeting; high quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156647,"accession_number":"0001606498-25-000064","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos CFO transition: Greiner departs, Pickett named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Greiner leaves Avanos effective April 18, 2025; receives $2.1M severance, prorated 2025 bonus, and 6 months COBRA.","Warren Machan ends role as Interim CFO April 14; will consult at $60K/month through April 30, forfeiting $45K second bonus.","Jason Pickett, formerly VP Tax and Treasurer, appointed Interim CFO and Treasurer as of April 14.","Greiner's special equity awards (44,189 + 10,000 RSUs) vest immediately; all other unvested awards cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156645,"accession_number":"0001606498-25-000063","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos appoints David Pacitti as CEO, effective April 14, 2025; compensation disclosed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Pacitti, former Siemens Healthineers Americas President, becomes CEO effective April 14, 2025.","Compensation: $1.05M base salary, 110% bonus target, $5M annual LTI target for 2026.","One-time equity awards: $3.5M PRSUs (stock price hurdles $20-$33) and $3.5M TRSUs (3-year vest).","Receives $500K cash sign-on; also serves on Orchestra BioMed (OBIO) board since March 2024.","Interim CEO Michael Greiner to continue until Pacitti starts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175068,"accession_number":"0001606498-25-000057","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos Medical names David Pacitti as CEO, effective April 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Pacitti appointed CEO of Avanos Medical, effective April 14, 2025.","Pacitti was President & Head of the Americas at Siemens Healthineers.","Base salary $1.05M, bonus target 110%, 2026 LTI target $5M.","One-time $500K cash sign-on and $7M in equity awards ($3.5M PRSUs + $3.5M TRSUs).","Pacitti will succeed interim CEO Michael Greiner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175067,"accession_number":"0001606498-25-000022","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q4 and FY2024 results; specific figures not available in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated February 26, 2025 for the three months and year ended December 31, 2024.","Exhibit 99.1 containing detailed financial data was referenced but not included in the provided text.","Common stock trades on NYSE under ticker AVNS."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":687800000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175066,"accession_number":"0001606498-25-000019","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos Medical at JP Morgan conference; no specific financial metrics disclosed in available text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation by Interim CEO Michael Greiner at 43rd Annual JP Morgan Healthcare Conference on January 13, 2025.","Exhibit text is truncated; only introductory remarks are visible, no numerical results or guidance provided.","No changes to previously disclosed business plans or objectives were noted in the incomplete text.","Filing is under Regulation FD; presentation is furnished, not filed, per standard practice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192021,"accession_number":"0001606498-24-000094","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos Medical formalizes Interim CFO consulting agreement with Warren Machan through May 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Warren Machan appointed Interim CFO effective Oct 28, 2024; consulting agreement formalized Dec 2, 2024.","Consulting term runs through May 31, 2025; either party may terminate with 30 days' notice.","Monthly fees: $45,000 through Feb 2025, then $60,000 for Mar-May 2025; plus two $45,000 cash bonuses.","Bonuses tied to continued service through Feb 28 and May 31, 2025, and satisfactory performance as determined by CEO.","Independent contractor arrangement; no equity or employee benefits; non-solicitation for one year after term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192020,"accession_number":"0001606498-24-000089","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avanos Medical authorizes new $25M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved up to $25.0 million in common stock repurchases over one year.","Repurchases to be made at management's discretion on open market or via private transactions.","Program will not commence until at least one full trading day after release of any material non-public info.","Company is not obligated to repurchase any specific amount; program may be suspended or discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192019,"accession_number":"0001606498-24-000082","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"CEO Joseph Woody retires; CFO Michael Greiner named interim CEO; Warren Machan interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Joseph Woody retired as CEO and board member effective Oct 28, 2024; will consult through Apr 30, 2025 at $84,618/month.","Michael Greiner (SVP/CFO/CTO) appointed interim CEO; receives $600k salary, $83k/month stipend, and $1M RSU grant.","Warren Machan (former SVP Business Strategy) appointed interim CFO; compensation not yet determined.","Board will conduct a search for permanent CEO; Greiner is leading candidate but will evaluate other candidates.","Company reported Q3 2024 financial results via press release on Oct 30; specific figures not included in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208493,"accession_number":"0001606498-24-000074","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q2 2024 results; filing lacks detailed financials","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Results announced for three and six months ended June 30, 2024.","No specific revenue, EPS, or segment figures available in provided text.","Guidance or outlook not mentioned in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":337800000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208492,"accession_number":"0001606498-24-000069","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos Medical appoints Indrani Franchini to Board of Directors, effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment fills a vacancy; Franchini will serve on Audit and Compliance Committees.","Compensation includes $70,000 annual cash retainer, $12,500 Audit, $7,500 Compliance, and $190,000 RSU grant.","Board now comprises 6 directors (5 independent) with 3 women, 2 ethnically diverse.","Franchini previously EVP/CLO at Alnylam, EVP/CCO at Alexion, and roles at Hess and Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226186,"accession_number":"0001606498-24-000060","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos appoints Sigfrido Delgado as SVP, Integrated Supply Chain","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sigfrido (Sig) Delgado named Senior Vice President, Integrated Supply Chain, effective May 13, 2024.","Appointment announced via press release on May 13, 2024.","Delgado will oversee Avanos' global supply chain operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226185,"accession_number":"0001606498-24-000055","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q1 2024 results; key figures not available in 8-K","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced results for three months ended March 31, 2024.","No specific EPS, revenue, or guidance figures included in filing text or exhibit.","Investors should refer to the full press release for detailed financial data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":166100000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226184,"accession_number":"0001606498-24-000053","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avanos Medical stockholders elect all five director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors: Gary Blackford, Lisa Egbuonu-Davis, Patrick O'Leary, Julie Shimer, Joseph Woody; each received over 39M votes for.","Ratified Deloitte & Touche as independent auditor for 2024 with 42.5M votes for vs 435k against.","Advisory vote on NEO compensation approved with 38.5M votes for, 2.1M against, and 2.3M broker non-votes.","About 93% of outstanding shares represented (42.99M shares) at the April 25, 2024 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245251,"accession_number":"0001606498-24-000016","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical Q4 net sales $173.3M (-4.6% YoY); 2024 outlook $685-$705M revenue, adj. EPS $1.30-$1.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.","Q4 GAAP diluted EPS $0.24 (vs $0.21); adjusted EPS $0.36 (vs $0.45). Full-year GAAP loss $(0.21) (vs $0.46 EPS); adjusted EPS $1.03 (vs $1.00).","Free cash flow for 2023 was $14.6M, down from $71.6M in 2022; Q4 outflow $3.4M.","Completed sale of respiratory health business (Oct 2) and acquired Diros Technology (July 24) to focus on Pain Management and Digestive Health.","2024 guidance: net sales $685-$705M (organic growth 3%-6%), adj. gross margin 59.5%-60.5%, adj. diluted EPS $1.30-$1.45."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":673300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245250,"accession_number":"0001606498-24-000002","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical issues preliminary Q4/FY2023 results; no figures in filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Announced selected unaudited preliminary results for Q4 and full year ended Dec 31, 2023.","Press release furnished as Exhibit 99.1 but actual financial data is not included in filing text.","No specific revenue, EPS, or guidance numbers disclosed in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":673300000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262705,"accession_number":"0001606498-23-000077","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q3 2023 results; no financial details available in filing text","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filed 8-K on Nov 1, 2023 announcing Q3 earnings results for period ended Sept 30, 2023.","Press release issued as Exhibit 99.1 but not included in provided text.","Unable to extract revenue, EPS, or segment data from available information.","Recommend reviewing full press release for specific financial figures and guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":500000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262704,"accession_number":"0001606498-23-000071","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Avanos closes sale of Respiratory Health business to SunMed for $110M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Divestiture of Avanos' Respiratory Health business closed Oct 2, 2023; $110M cash purchase price subject to adjustments for indebtedness, inventory, and chargebacks.","Amendment adds Assumed Chargeback Liabilities definition; purchase price reduced by estimated chargeback amount with final adjustment by Oct 31, 2023.","India-related assets transferred separately at $910,000 purchase price; India purchase agreement to be executed post-closing.","Indemnification cap for India VAT losses set at $172,000; other amendments modify purchase price calculation and escrow details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279895,"accession_number":"0001606498-23-000067","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos clarifies Q2 2023 results beat consensus after third-party error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third party incorrectly reported Avanos missed consensus; total sales including discontinued RH business were $199.8M.","Adjusted diluted EPS including discontinued ops was $0.37, ahead of consensus.","Continuing operations: net sales $169.4M, diluted loss per share $0.09, adjusted EPS $0.24.","RH business operating results reported as discontinued operations due to planned divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279894,"accession_number":"0001606498-23-000063","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Avanos Q2 sales $169.4M, adjusted EPS $0.24; FY2023 adjusted EPS guidance $1.05-$1.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net sales $169.4M (-0.9% YoY); net loss $4.3M vs net income $4.8M a year ago.","Adjusted diluted EPS $0.24 vs $0.26; adjusted EBITDA flat at $22.9M.","Closed Diros Technologies acquisition (RFA) in July; recorded $72.3M impairment on Respiratory Health divestiture.","UK NICE recommends RFA for osteoarthritic knee pain, potentially improving Pain Management reimbursement.","FY2023 outlook: adjusted EPS $1.05-$1.15, adjusted gross margin >59%, H2 organic growth low single-digit."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":328700000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279893,"accession_number":"0001606498-23-000060","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avanos Medical authorizes $25M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved $25M one-year share repurchase program on July 28, 2023.","Repurchases allowed on open market or privately, at management's discretion.","Program will not begin until at least one trading day after release of any material non-public info.","Company not obligated to repurchase any amount; program may be suspended or discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298369,"accession_number":"0001606498-23-000052","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Avanos Medical agrees to acquire Diros Technology, RF pain management portfolio strengthened","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal includes all outstanding shares of Diros Technology; financial terms not disclosed.","Financed via existing credit facility and available cash; expected to close Q3 2023.","Diros is a Toronto-based manufacturer of radiofrequency ablation products for chronic pain.","Avanos expects the acquisition to be immediately accretive to revenue, gross margins, operating margins, and EPS.","Diros' RF Trident technology complements Avanos' existing COOLIEF Cooled Radiofrequency product line."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298368,"accession_number":"0001606498-23-000050","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Avanos sells Respiratory Health to SunMed for $110M, accelerates portfolio focus","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Definitive agreement to sell substantially all RH assets for $110M cash; close expected late 2023.","Transaction includes BALLARD, MICROCUFF, endOclear brands and two manufacturing facilities in Mexico.","Avanos will provide transition services; net proceeds enhance balance sheet for M&A in core categories.","Divestiture is key component of three-year transformation to focus on Digestive Health and Pain Management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298367,"accession_number":"0001606498-23-000039","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"Avanos Medical reports Q1 results and holds annual meeting; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Q1 2023 earnings released May 3, 2023; no financial figures provided in the filing.","Annual meeting held Apr 27, 2023; 94.23% of shares represented (43,916,111 shares).","All six director nominees elected; Dr. Julie Shimer received lowest support (35.5M for, 6.2M withheld).","Delaware auditor ratified (43.5M for, 0.27M against); advisory say-on-pay approved (38.96M for, 2.59M against).","LTIP amended to increase authorized shares by 1.25M (39.96M for, 1.59M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318600,"accession_number":"0001606498-23-000023","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avanos Medical appoints Dr. Lisa Egbuonu-Davis to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Egbuonu-Davis appointed as independent director effective March 6, 2023; serves on Compliance and Governance Committees.","She receives $70,000 annual cash retainer, $7,500 Compliance Committee fee, $5,000 Governance Committee fee, and $190,000 in RSUs.","Board now comprises six directors: five independent, two women, one ethnically diverse.","Egbuonu-Davis is VP Medical Innovations at DH Diagnostics (Danaher affiliate); previously VP at Sanofi and roles at Pfizer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318599,"accession_number":"0001606498-23-000016","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical files 8-K for Q4 and FY2022 results; press release text not provided in this filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Filing reports results for three months and year ended December 31, 2022.","Press release attached as Exhibit 99.1 but not included in the provided text.","No specific financial figures (revenue, EPS, guidance) available to summarize."],"consensus_eps_estimate":null,"consensus_eps_actual":1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":820000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318596,"accession_number":"0001606498-23-000018","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K/A","filed_at":"2023-02-21T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Avanos Medical estimates $20M-$25M cash costs for transformation; expects $45M-$55M gross savings by 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash expenses of $20M-$25M for transformation: $9M-$12M consulting/retention, $8M-$11M manufacturing/supply chain.","Employee severance and benefits costs estimated at $6M-$8M.","Anticipated savings of ~$10M in 2023; gross savings of $45M-$55M by 2025, mostly in 2024.","Plan includes combining Chronic Care and Pain franchises, exiting low-margin products, and cost management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318598,"accession_number":"0001606498-23-000013","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avanos Medical amends CEO severance to 2.5x pay; SVP International resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO severance payout multiple increased from 2x to 2.5x on qualified termination.","Arjun R. Sarker, SVP International, resigns effective May 10, 2023.","Changes approved by Compensation Committee on Feb 14, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":318597,"accession_number":"0001606498-23-000011","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.05","5.02","7.01","9.01"],"status":"ready","headline":"Avanos launches 3-year transformation; CFO Greiner adds Chief Transformation Officer role; SVP Haydon to depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three-year plan: combine Chronic Care & Pain franchises, exit low-margin products, cost management, and focused M&A.","CFO Michael Greiner assumes additional role of Chief Transformation Officer to lead the transformation.","Kerr Holbrook appointed SVP & Chief Commercial Officer, overseeing combined commercial organization.","William D. Haydon, SVP & GM Pain Franchise, to depart March 31, 2023; receives $972K severance plus up to $300K transition bonus.","Company currently unable to estimate total transformation costs; will file amended 8-K within four business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336835,"accession_number":"0001606498-22-000082","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avanos appoints Sudhakar Varshney as SVP Global Supply Chain and Procurement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sudhakar Varshney appointed as Senior Vice President, Global Supply Chain and Procurement.","Appointment announced on November 14, 2022; effective immediately.","Varshney to oversee worldwide supply chain and procurement operations for Avanos Medical."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336834,"accession_number":"0001606498-22-000077","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avanos Medical reports Q3 2022 earnings; no specific data provided in filing excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Quarter ended September 30, 2022 results disclosed on November 2, 2022.","Key financial metrics (revenue, net income, EPS) not available from the supplied text.","Investors should consult the full press release for complete details."],"consensus_eps_estimate":null,"consensus_eps_actual":0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":602500000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336833,"accession_number":"0001606498-22-000073","cik":1606498,"company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Maria Sainz to resign from Avanos Board effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Maria Sainz notified Avanos of resignation from Board, effective January 1, 2023.","Resignation is not due to any disagreement with the Company's operations, policies, or practices.","Ticker: AVNS; effective date allows for orderly transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1160084333.052642,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-11T23:59:59+00:00|336833"}